Literature DB >> 33492335

Comprehensive analysis of tumor mutation burden and immune microenvironment in gastric cancer.

Jie Yu1, QianYun Zhang2, MengChuan Wang1, SiJia Liang3, HongYun Huang1, Lang Xie1, ChunHui Cui1, JinLong Yu1.   

Abstract

Tumor mutation burden (TMB) was a promising marker for immunotherapy. We aimed to investigate the prognostic role of TMB and its relationship with immune cells infiltration in gastric cancer (GC). We analyzed the mutation landscape of all GC cases and TMB of each GC patient was calculated and patients were divided into TMB-high and TMB-low group. Differentially expressed genes (DEGs) between the two groups were identified and pathway analysis was performed. The immune cells infiltration in each GC patient was evaluated and Kaplan-Meier analysis was performed to investigate the prognostic role of immune cells infiltration. At last, hub immune genes were identified and a TMB prognostic risk score (TMBPRS) was constructed to predict the survival outcome of GC patients. The relationships between mutants of hub immune genes and immune infiltration level in GC was investigated. We found higher TMB was correlated with better survival outcome and female patients, patients with T1-2 and N0 had higher TMB score. Altogether 816 DEGs were harvested and pathway analysis demonstrated that patients in TMB-high group were associated with neuroactive ligand-receptor interaction, cAMP signaling pathway, calcium signaling pathway. The infiltration of activated CD4+ memory T cells, follicular helper T cells, resting NK cells, M0 and M1 macrophages and neutrophils in TMB-high group were higher compared than that in TMB-low group and high macrophage infiltration was correlated with inferior survival outcome of GC patients. Lastly, the TMBPRS was constructed and GC patients with high TMBPRS had poor prognosis.
© 2021 The Author(s).

Entities:  

Keywords:  Gastric cancer; Immune cells infiltration; Prognosis; Tumor mutation burden

Mesh:

Year:  2021        PMID: 33492335      PMCID: PMC7921293          DOI: 10.1042/BSR20203336

Source DB:  PubMed          Journal:  Biosci Rep        ISSN: 0144-8463            Impact factor:   3.840


  47 in total

Review 1.  Cytokines in cancer pathogenesis and cancer therapy.

Authors:  Glenn Dranoff
Journal:  Nat Rev Cancer       Date:  2004-01       Impact factor: 60.716

2.  Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Authors:  Leena Gandhi; Delvys Rodríguez-Abreu; Shirish Gadgeel; Emilio Esteban; Enriqueta Felip; Flávia De Angelis; Manuel Domine; Philip Clingan; Maximilian J Hochmair; Steven F Powell; Susanna Y-S Cheng; Helge G Bischoff; Nir Peled; Francesco Grossi; Ross R Jennens; Martin Reck; Rina Hui; Edward B Garon; Michael Boyer; Belén Rubio-Viqueira; Silvia Novello; Takayasu Kurata; Jhanelle E Gray; John Vida; Ziwen Wei; Jing Yang; Harry Raftopoulos; M Catherine Pietanza; Marina C Garassino
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

3.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean-Jacques Grob; Piotr Rutkowski; Christopher D Lao; C Lance Cowey; Dirk Schadendorf; John Wagstaff; Reinhard Dummer; Pier F Ferrucci; Michael Smylie; David Hogg; Andrew Hill; Ivan Márquez-Rodas; John Haanen; Massimo Guidoboni; Michele Maio; Patrick Schöffski; Matteo S Carlino; Céleste Lebbé; Grant McArthur; Paolo A Ascierto; Gregory A Daniels; Georgina V Long; Lars Bastholt; Jasmine I Rizzo; Agnes Balogh; Andriy Moshyk; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2019-09-28       Impact factor: 91.245

4.  Elevated levels of tumour apolipoprotein D independently predict poor outcome in breast cancer patients.

Authors:  Tanja Jankovic-Karasoulos; Tina Bianco-Miotto; Miriam S Butler; Lisa M Butler; Catriona M McNeil; Sandra A O'Toole; Ewan K A Millar; Andrew J Sakko; Alexandra I Ruiz; Stephen N Birrell; Robert L Sutherland; Theresa E Hickey; Wayne D Tilley; Carmela Ricciardelli
Journal:  Histopathology       Date:  2020-05-15       Impact factor: 5.087

5.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-03-21       Impact factor: 91.245

6.  First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.

Authors:  Leora Horn; Aaron S Mansfield; Aleksandra Szczęsna; Libor Havel; Maciej Krzakowski; Maximilian J Hochmair; Florian Huemer; György Losonczy; Melissa L Johnson; Makoto Nishio; Martin Reck; Tony Mok; Sivuonthanh Lam; David S Shames; Juan Liu; Beiying Ding; Ariel Lopez-Chavez; Fairooz Kabbinavar; Wei Lin; Alan Sandler; Stephen V Liu
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245

7.  Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.

Authors:  Arnaud Scherpereel; Julien Mazieres; Laurent Greillier; Sylvie Lantuejoul; Pascal Dô; Olivier Bylicki; Isabelle Monnet; Romain Corre; Clarisse Audigier-Valette; Myriam Locatelli-Sanchez; Olivier Molinier; Florian Guisier; Thierry Urban; Catherine Ligeza-Poisson; David Planchard; Elodie Amour; Franck Morin; Denis Moro-Sibilot; Gérard Zalcman
Journal:  Lancet Oncol       Date:  2019-01-16       Impact factor: 41.316

8.  Survival marker genes of colorectal cancer derived from consistent transcriptomic profiling.

Authors:  Jorge Martinez-Romero; Santiago Bueno-Fortes; Manuel Martín-Merino; Ana Ramirez de Molina; Javier De Las Rivas
Journal:  BMC Genomics       Date:  2018-12-11       Impact factor: 3.969

9.  The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis.

Authors:  Yongfeng Wu; Jinming Xu; Chengli Du; Yihua Wu; Dajing Xia; Wang Lv; Jian Hu
Journal:  Front Oncol       Date:  2019-11-05       Impact factor: 6.244

10.  Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.

Authors:  Jennifer N Brudno; Norris Lam; Danielle Vanasse; Yueh-Wei Shen; Jeremy J Rose; John Rossi; Allen Xue; Adrian Bot; Nathalie Scholler; Lekha Mikkilineni; Mark Roschewski; Robert Dean; Raul Cachau; Philippe Youkharibache; Rashmika Patel; Brenna Hansen; David F Stroncek; Steven A Rosenberg; Ronald E Gress; James N Kochenderfer
Journal:  Nat Med       Date:  2020-01-20       Impact factor: 53.440

View more
  6 in total

1.  Characterization of Tumor Mutation Burden-Based Gene Signature and Molecular Subtypes to Assist Precision Treatment in Gastric Cancer.

Authors:  Cheng Wei; Minzhe Li; Shaofeng Lin; Jun Xiao
Journal:  Biomed Res Int       Date:  2022-05-13       Impact factor: 3.246

2.  Integrated weighted gene coexpression network analysis identifies Frizzled 2 (FZD2) as a key gene in invasive malignant pleomorphic adenoma.

Authors:  Zhenyuan Han; Huiping Ren; Jingjing Sun; Lihui Jin; Qin Wang; Chuanbin Guo; Zhen Tian
Journal:  J Transl Med       Date:  2022-01-05       Impact factor: 5.531

3.  An age stratified analysis of the biomarkers in patients with colorectal cancer.

Authors:  Hui Yao; Chengjie Li; Xiaodong Tan
Journal:  Sci Rep       Date:  2021-11-17       Impact factor: 4.379

4.  Mechanism investigation and experiment validation of capsaicin on uterine corpus endometrial carcinoma.

Authors:  Zhiheng Lin; Xiaohui Sui; Wenjian Jiao; Chong Chen; Xiaodan Zhang; Junde Zhao
Journal:  Front Pharmacol       Date:  2022-09-21       Impact factor: 5.988

5.  A bioinformatics framework to identify the biomarkers and potential drugs for the treatment of colorectal cancer.

Authors:  Xiaogang Leng; Jianxiu Yang; Tie Liu; Chunbo Zhao; Zhongzheng Cao; Chengren Li; Junxi Sun; Sheng Zheng
Journal:  Front Genet       Date:  2022-09-27       Impact factor: 4.772

6.  Identification of a Gene Prognostic Model of Gastric Cancer Based on Analysis of Tumor Mutation Burden.

Authors:  Weijun Ma; Weidong Li; Lei Xu; Lu Liu; Yu Xia; Liping Yang; Mingxu Da
Journal:  Pathol Oncol Res       Date:  2021-09-10       Impact factor: 3.201

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.